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RecommendationsToxoplasmosis manifests no clinical signs in 80% of cases in immunocompetent patient, causing immunization
characterized by the persistence of cysts, particularly in brain, muscles, and retina. Assessing the serological
status, based on testing for serum toxoplasma IgG and IgM antibodies, is essential in cases that are increasingly
at risk for the more severe disease forms, such as congenital or ocular toxoplasmosis. This disease also exposes
immunosuppressed patients to reactivation, which can lead to more widespread forms and increased mortality.
By interpreting the serological results, we can estimate the risk of contamination or reactivation and deﬁne
appropriate prophylactic and preventive measures, such as hygienic and dietetic, therapeutic, biological, and
clinical follow-up, according to the clinical context.Wehereby propose practical approaches based on serological
data, resulting from a consensus of a group of experts from the French National Reference Center Network for
Toxoplasmosis, according to both routine and speciﬁc clinical situations.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In France, a national program for prevention of congenital toxoplas-
mosis has been set up in 1978 (Villena et al., 2010), and the incidence of
toxoplasmic seroconversion during pregnancy in 2012was estimated at
1.9/1000 susceptible pregnant women (Ambroise-Thomas et al., 2001;
Bellali et al., 2013; Nogareda et al., 2014). For the same year, the global
prevalence of congenital toxoplasmosis was estimated at 2.58 per
10,000 live; births in France and 204 cases of congenital toxoplasmosis
were observed. Of these, 52.5% were diagnosed at birth, and
approximately 90% were asymptomatic. Updated ﬁndings can be
found on the National Reference Center on Toxoplasmosis Web site:
http://cnrtoxoplasmose.chu-reims.fr/.
The systems currently in place formonitoring congenital toxoplasmo-
sis in European countries greatly vary and are principally dependent on
prevalence rates. A recent investigation aimed to describe these different
systems in Europe (Bénard et al., 2008). The results showed that, of the 28are listed at the end of the paper.
33-368853809.
olﬁ@unistra.fr (E. Candolﬁ).
. This is an open access article undercountries investigated, only 4 possessed a speciﬁc monitoring system for
congenital toxoplasmosis: Italy, Denmark, Germany, and France.
2. Immune response to toxoplasma infection
In 1948, Sabin and Feldman developed a serologic assay called the
dye test (Sabin and Feldman, 1948) for conducting serological diagnosis
of toxoplasmosis, an infection caused by an intracellular apicomplexan
parasite infecting all nucleated cells in the human body. This assay has
radically altered our view of this conﬁdential clinical disease, which
was previously associated onlywith a few cases of congenital and ocular
toxoplasmosis. The 2 researchers later discovered, along with others,
that toxoplasmosis was, in fact, the most widespread parasitic infection
in the world that primarily manifested no clinical signs in 80% of cases
(Montoya and Liesenfeld, 2004). One section of the population particu-
larly at risk during an acute infection are pregnant women, due to
toxoplasma's ability to cross the placental barrier and infect the vulner-
able fetus before it can acquire immunity. The other groups at risk are
immunosuppressed patients that have never been in contact with toxo-
plasma parasites (Belanger et al., 1999; Weiss and Dubey, 2009). In its
acute infection form, toxoplasma spreads through all the organs, andthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. Advice algorithm for toxoplasma serology with negative IgG and IgM. Adapted from Villard et al., 2011.
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innate immunity and the rise of speciﬁc acquired immunity, including
humoral immunity (Robert-Gangneux and Darde, 2012). All isotypes
are produced by stimulated B cells: namely, IgM, IgG, IgA, and IgE.
These antibodies are functionally important as they are known for
blocking cell invasion, lysing parasites by activating complement path-
ways and the catalytic activity of NK and CD8+T cells, or by phagocyto-
sis. In immune-privileged organs, such as the muscles, brain, and eyes,
this parasite remains in cysts in the form of bradyzoites for the rest of
the patient's life. Reactivation may thus occur in immunosuppressed
patients, such as those diagnosedwithAIDS,which can lead to a dissem-
inated toxoplasmosis with a high rate of mortality if no speciﬁc treat-
ment is administered (Petersen et al., 2006). However, in the retina,
reactivation can occur in perfectly immunocompetent patients, leading
to retinochoroiditis (Burnett et al., 1998). Nevertheless, whether there
are any clinical signs, detecting toxoplasmic antibodies is key to the
serological diagnosis of toxoplasmosis. The ability to identify T. gondii
infection is still today primarily based on serological assay detection
of IgM, IgG, and IgA levels. IgMs are the ﬁrst antibodies to appear,
usually 1 week after the infection. Their levels rise until peaking after
1–3 months. A slow decrease then occurs over the next 9 months until
negativation. However, one part of the patient population (9–27%) has
been found to exhibit a persistent IgM antibody response that remains
for 2 years or more (Bobic et al., 1991; del Bono et al., 1989; Gras
et al., 2004). Toxoplasmic IgG appears after 2 weeks of infection and
peaks at 3 months. It then remains at a plateau level for 6 months and
after 1 year starts to slowly decrease to lower levels until the end of in-
fected subject's life due to the persistence of latent cysts in immune-
privileged organs. The antigen binding avidity of these IgG antibodiesrises slowly during the ﬁrst 4 months. The kinetic of IgA production is
similar to those of IgM, the peak of IgA is reached later than IgM, and
the IgA antibodies persist over 3 or 4 months following infection
(Bessieres et al., 1992). The toxoplasma immunological status can bede-
termined by serological screening using various methods that must be
adapted to the clinical situation, aswell as to the prevalence of toxoplas-
mosis in the setting where the assays are performed.
The National Reference Center for Toxoplasmosis has established
ﬂowcharts providing basic interpretation of toxoplasmic serology in
seronegative pregnant women based on the detection of IgM and IgG
alone. These ﬂowcharts are embedded in the French programof preven-
tion of congenital toxoplasmosis.
This study sought to deﬁne other ﬂowcharts of immunocompetent
patients in both routine cases and speciﬁc clinical situations, such as
congenital toxoplasmosis, immunosuppressed situations, and ocular
toxoplasmosis.
3. Methods
It is crucial to choose the right methods at the right cost. However,
the choice of method may be informed by the prevalence rates in
the country (Stillwaggon et al., 2011) and local or national recommen-
dations for the follow-up and may also depend on the observed clinical
situation, for example, involving pregnantwomen, newborns, immuno-
suppressed patients, or those presenting with decreased vision. The
methods' performance is highly variable (Bobic et al., 2009; Petersen
et al., 2005; Villard et al., 2012, 2013), and it can be difﬁcult to choose
between thehistorical assays, such as dye test, hemagglutination, agglu-
tination, immunoglobulin M immunosorbent agglutination (ISAGA),
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Fig. 2. Serological monitoring for toxoplasma serology with positive IgG and negative IgM. Adapted from Villard et al., 2011.
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ones or even the more conﬁdential methods such as immunoblot
(Ashburn et al., 2001; Evans and Ho-Yen, 2000; Franck et al., 2008;
Johnson et al., 1989).
These methods can be separated into 2 groups in order to optimize
the interpretation of serological data, the ﬁrst included fast or automat-
ed screening and the second used for conﬁrmatory tests. Screening
methods are either low on expense or limited to a small amount of
serum, e.g., hemagglutination and agglutination, or are automated in
cases of a larger screening process like enzyme-linked immunosorbent
assay (ELISA) or CLIA (Chemiluminescence immuno assay). Conﬁrma-
tion methods are mostly in-house, complex, or costly methods, such
as dye test, IFAT, immunoblot, and ISAGA. These last methods should
be handled exclusively in reference centers.
Finally, the last degree of complexity in the serological diagnosis of
toxoplasmosis is the global interpretation of the data acquired by these
different methods. Interpreting these data can be a difﬁcult exercise,
and the vast choice of available complementary methods adds to the
complexity of the diagnosis. The conclusions drawn from the resultingdata can lead to primary prophylaxis; speciﬁc treatment; serological
follow-up; and more invasive investigation for toxoplasma forms, such
as amniocentesis, bronchoalveolar lavage, or spinal ﬂuid sampling.
4. Routine serological situations
4.1. Absence of IgG and IgM (Fig. 1)
The goal of serology testing inpregnantwomen is thus to assess if they
are at risk, sparse false negatives are allowed, while a false positive is un-
acceptable as anyhygienic anddietetic preventivemeasureswouldnot be
provided. This screeningmethod is based on the detection of toxoplasmic
IgG, and the assays should therefore achieve a speciﬁcity of over 99.9%.
The absence of IgG and IgMantibodies rules out the possibility of a recent
infectionmore than or equal than to 7 days in absence of recent contamina-
tion of less than 1month, and it is advisable to provide hygienic and dietetic
preventivemeasures (AFSSA, 2006), for pregnantwomen and immunocom-
promisedpatients in thesecases. For those, a serological follow-up is required,
depending on the clinical situation. Public health authorities in France have
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Fig. 3. Serological monitoring for toxoplasma serology with negative IgG and positive IgM. Adapted from Villard et al., 2011.
25O. Villard et al. / Diagnostic Microbiology and Infectious Disease 84 (2016) 22–33implemented a congenital toxoplasmosis prevention program that includes a
monthly serological screening until delivery (Nogareda et al., 2014) and
for immunocompromised patients, every 6 months.
4.2. Presence of IgG and absence of IgM (Fig. 2)
The presence of speciﬁc IgG and absence of IgM immediately points
to a previous infection, and any kind of serological follow-up can thus be
discontinued, as the immunity is assumed to protect the fetus from any
reinfection. However, in some cases, the IgM antibodies may be evanes-
cent or even negative (Fricker-Hidalgo et al., 2013). It is typically recom-
mended to perform a second serology 3weeks later in order to track any
potential increase in IgG levels. Stable IgG levels indicate a diagnosis of
chronic toxoplasmosis. A signiﬁcant increase in IgG levels depending
on used techniques leads to tests to determine IgG avidity. In cases
of high IgG avidity, reinfection or reactivation is strongly suspected. Se-
rological follow-up is unnecessary if this situation occurs in an immuno-
competent subject. On the contrary, if IgG avidity is low or equivocal in a
pregnant woman, the date of contamination cannot be speciﬁed, and
adapted management must be initiated, depending on gestational age.4.3. Absence of IgG and presence of IgM (Fig. 3)
Toxoplasma parasites reach the placenta extremely quickly, and
early treatment reduces the risk of mother-to-child transmission, also
enabling the disease severity to be reduced (Desmonts et al., 1990;
Moncada and Montoya, 2012). The methods should therefore enable
very early detection of IgM, the ﬁrst isotype to appear, and thus, well-
adapted management can be started based on amniocentesis antenatal
diagnosis and treatment. In this context, the sensitivity of the reagents
detecting IgM is heightened. IgG antibodies are, however, crucial in
conﬁrming seroconversion and infection. The detection of IgM associat-
ed with absence of the IgG should evoke a recent infection, requiring
conﬁrmation by a second sampling 2 weeks later. First, the speciﬁcity
of IgM should be conﬁrmed bymeans of a referencemethod using a dif-
ferent technical background, such as ISAGA-IgM or immunoﬂuores-
cence. If the IgM is not thus conﬁrmed, the presence of nonspeciﬁc
IgM is strongly suspected or a false-positive reaction. The result of the
second sampling conducted 2 weeks later is crucial. Then if another
isotype IgG/IgA is detected in addition to IgM, acute infection is con-
ﬁrmed (Gutierrez et al., 1997). If IgM levels remain stable and no IgG
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follow-up should be performed, tracking any IgG seroconversion over
the following 2 weeks. The appearance of low concentrations of IgG an-
tibodies is variable according the used tests. A recent study demonstrat-
ed a better sensibility with the reactive of immunoblot in the early
detection of the IgG and conﬁrmation of toxoplasmic seroconversion
(Jost et al., 2011). Acute toxoplasmosis in a pregnant woman necessi-
tates adapted management depending on gestational age. If the patient
is immunosuppressed, the treatment method is deﬁned based on clini-
cal background and immunosuppression level.
4.4. Presence of IgG and IgM (Fig. 4)
The above-mentioned presence of IgM detected in the disease's
chronic stage has led to efforts to distinguish between the acute and
chronic stages in cases where IgM is present in the serum, and measur-
ing IgG avidity is a precious tool in achieving this. The discovery that IgG
matures over time resulted in using this property to distinguish an acute
phase, based on poorly competent IgG, from a chronic stage,with highly
competent IgG (Villard et al., 2013). Thismethodhas enabled us tomore
clearly establish the date of contamination in 1 serum by ruling out re-
cent infection, i.e., typically deﬁned as manifesting in the previous
4 months (Ashburn et al., 2001; Holliman et al., 1994). It has also
aided in more precisely determining the risk of transmission to the
fetus with regard to pregnancy cases (Evans and Ho-Yen, 2000). Somereference centers (especially in the United States) use differential
agglutination (AC/HS) in conjunction with avidity (Montoya et al.,
2007). The AC/HS test's window for excluding a recently acquired
infection appears to be remarkably longer than that for the avidity test
(Dannemann et al., 1990).
During pregnancy, it is necessary to determine as precisely as possi-
ble the date of contamination in order to evaluate the risk of transpla-
cental transmission and fetal infection. In the absence of any previous
biological test ﬁndings, IgG avidity must be assessed, enabling a precise
deﬁnition of the date of infection (Candolﬁ et al., 2007). If IgG avidity is
high, a recent infection lasting less than 16–20weeks depending on the
commercial assay can be ruled out. If IgG avidity is low, or equivocal, a
recent infection cannot be excluded, and a follow-up analyzing IgG ki-
netics can provide the precise date of infection. An IgG titer remaining
stable over a 2-week period constitutes a marker of a latent infection
lasting at least 2 or 4months depending of used techniques and individ-
ual variability. A signiﬁcant increase, deﬁned as at least a 2-fold increase
in a no-treatment context, is a marker of acute infection and necessi-
tates adapted management depending on gestational age and the esti-
mated date of infection.
4.5. Presence of equivocal titer of IgG without IgM (Fig. 5)
This kind of serological proﬁle raises the problem of precisely char-
acterizing a subject's immune status which depends on the threshold
Equivocal IgG
Negative IgM
Immunocompetent patient
Immunocompromised patient
Pregnancy
IgG antibodies detection by a
different method
Seronegative
Immunocompromised patient
Pregnancy
Serological
screening to adapt
advices for avoiding
infection
Probable latent infection
Immunocompromised
patient
Managment and treatment
varies with clinical
presentation and degree
of immunosupression
Pregnancy
To confirm in a
second serum in 3
weeks
Equivocal serology
Dye test
Immunoblot
Negative Positive
Seronegative Latentinfection
Fig. 5. Advice algorithm for toxoplasma serology with equivocal IgG and negative IgM. Adapted from Villard et al., 2011.
27O. Villard et al. / Diagnostic Microbiology and Infectious Disease 84 (2016) 22–33of the technique. In the speciﬁc case of pregnancy, the immune status
directly inﬂuences whether a serological follow-up is initiated. It is
therefore highly recommended tomonitor the IgG titer using a different
method (Lesle et al., 2011). A reference method like dye test or immu-
noblot should be conducted in an expert laboratory to conﬁrm for low
titers of IgG with immune enzymatic tests (Fig. 6). As a result, pregnant
women and immunocompromised patients are provided with hygienic
recommendations or prescribed serological follow-up, according to
French national guidelines and with consideration of clinical status in
immunocompromised patients.
Finally, universal monthly maternal screening for congenital toxo-
plasmosis, with follow-up and treatment designed according to French
protocols, has been found to be cost-saving if the methods are well
adapted to the local seroprevalence (Stillwaggon et al., 2011).
5. Speciﬁc clinical situations
Some speciﬁc clinical situations, apart from the serological screening
of immunocompetent patients, require speciﬁc methods to be imple-
mented, supported by speciﬁc coverage.
5.1. Prenatal and postnatal follow-up in a suspected case of congenital
toxoplasmosis (Figs. 7 and 8)
Maternal infection leads to the risk of a transplacental passage of
toxoplasma parasites to the fetus and may cause congenital toxoplas-
mosis, resulting potentially in abortion or fetal death (Villena et al.,
2010). Severe symptoms, such as hydrocephalus, microcephaly or
encephalitis, or sequelae, such as visual impairment, intracranial calciﬁ-
cations, or mental retardation, can be observed in affected infants(Montoya and Liesenfeld, 2004; Weiss and Dubey, 2009). The severity
and percentage of infection depend on the date of contamination during
pregnancy. It is crucial to determine the immunological status of the
pregnant woman. In his 1974 study, Desmonts reported that those
who were seropositive prior to pregnancy did not transmit infection
to the fetus (Desmonts et al., 1960), though some exceptions were
observed in cases of recontamination by more virulent strains
(Desmonts et al., 1990).When toxoplasmaDNA is detected in the amni-
otic ﬂuid, the treatment is changed to a pyrimethamine and sulfon-
amide association, with postnatal clinical follow-up. If no prenatal
diagnosis is established or if the data cannot conﬁrm congenital toxo-
plasmosis (CT), a serological and parasitological diagnosis is performed
at birth, and serological follow-up is initiated.
In France, the national program to prevent congenital toxoplasmosis
created in 1978 and the surveillance system by the French National In-
stitute of Public Health Surveillancewith The National Reference Centre
for toxoplasmosis established in 2007 is associated with a lower rate of
severe forms of congenital toxoplasmosis. In 2012, prevalence of CTwas
estimated at 2.58 per 10,000 births with a prevalence of severe forms of
0.09 per 10,000 births. The majority of infections are asymptomatic
(Villena et al., 2010).
Postnatal screening and follow-up of neonates can be a complemen-
tary management strategy to prenatal diagnosis or an alternative in
countries with no regular serological screening of pregnant women.
Screening at birth can be associatedwith parasite detection in the amni-
otic ﬂuid, placenta, or cord blood serum, along with detection of IgM,
IgA, or IgG in the cord blood serum and newborn serum. Positive PCR
alone in placenta may be related to residual DNA from dead parasites
or placental persistence with no fetal transmission (Ajzenberg et al.,
2002; Fricker-Hidalgo et al., 2007; Robert-Gangneux et al., 2011).
Fig. 6. IgG immunoblot. 1. Positive control with 5 bands corresponding to 30, 31, 33, 40,
and 45 kDa. 2. False-positive serum with an equivocal titer of IgG. 3. Positive patient
with the 5 bands.
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ﬁrst 10 days, of maternal origin. IgG has a half-life of 3 weeks; and
IgM and IgA, 10 days. Classical methods are unable to distinguish be-
tween these maternally transmitted IgG antibodies or contamination-
resulting IgM and IgA antibodies and those that are newly synthesized
newborn antibodies. Follow-up is necessary to conﬁrm CT. Speciﬁc neo-
nate antibody isotypes should be tracked using methods able to detect
low levels of these antibodies, which should also conﬁrm their neonatal
origin (Magi and Migliorini, 2011). A comparative immunoblot test for
speciﬁc IgG and IgM analysis from paired mother-newborn at birth
and from follow-up sera of neonates can conﬁrm a CT diagnosis. Differ-
ent band patterns frommothers andneonates at birth indicate a speciﬁc
antibody neosynthesis in the newborn serum, also conﬁrming CT. A
comparison of this proﬁle with IgM can rule out contamination of the
cord serum with maternal serum, especially for the detected IgM anti-
bodies (Fig. 8).
The sensitivity of immunoblot at birth is 48–50% for IgG, reaching
65–79% when combined with Western blot (WB) detection of IgM
(Tissot Dupont et al., 2003) and achieving as high as 95.8% in the com-
bination of WB IgMwith prenatal and serological neonatal tests during
the ﬁrst month of life (L’Ollivier et al., 2012; Pinon et al., 2001).
IgG is the principal isotype that should be followed up by classical
methods, ensuring a precise determination of its titer (IU/mL or any
other units). IgG displays a long half-life of 3 weeks and should bemon-
itored until its disappearance.
Any modiﬁcation of the classical curve of IgG decay, either in terms
of stabilization or increase, is a clear indication of CT. However, this
process is long and costly. The detection of IgA or IgM during this period
enables a shorter follow-up while offering a clear indication of CT.5.2. Suspicion of ocular toxoplasmosis (Fig. 9)
Ocular toxoplasmosis (OT) is a major cause of posterior uveitis world-
wide. This disease is a form of chorioretinitis that can be the result of a con-
genital (Silveira et al., 2001)or acquireddiseasedue to acute infection, often
in the context of an acute disease outbreak (Holland, 1999; Montoya and
Remington, 1996; Stanford et al., 2006) or otherwise a reactivation of latent
disease embedded in the retina and choroid (Mets et al., 1996), leading to
multiple lesions that can cause blindness ifwidespread, especiallywhen in-
volving the macula area (Arevalo et al., 2010; Bodaghi et al., 2001). OT
should be always conﬁrmed by detection of either toxoplasma DNA using
PCR or of a local production of IgG and/or IgA antibodies. This conﬁrmation
enables a targeted treatment against toxoplasma and its subsequent in-
ﬂammation to be initiated in order to limit the cytolysis of retinal tissues
and development of larger scars, thereby improving visual acuity outcome.
The serology testing in these settings is unique due to the fact that the
assays need to detect intraocular T. gondii antibody production in the aque-
ous humor. Biological diagnosis should be carried out using aqueous humor
samples or is less frequently conducted in vitreous samples by means of
paracentesis. The serum should always be sampled simultaneously.
If the serum tests are negative for toxoplasma antibodies, all investi-
gations should be stopped in immunocompetent patients. When toxo-
plasma antibodies are detected, a PCR assay and detection of IgG
antibodies are conducted on ocular ﬂuid. A positive PCR conﬁrms the
toxoplasmic origin and enables early speciﬁc treatment to be initiated,
rapidly (Bastien, 2002; Bourdin et al., 2014). Furthermore, by genotyp-
ing the strain involved in the disease on DNA, we can improve our un-
derstanding of the impact of T. gondii strain genotypes on toxoplasmic
retinochoroiditis (Ajzenberg et al., 2009; Fekkar et al., 2011). In the
presence of a negative PCR, classical criteria should be applied to the
serum to determine if it is an acute infection or recurrence (Gilbert
and Stanford, 2000). In the event of an active infection, there is the
risk of blood-retinal barrier break-down, due to high choroiditis and an-
tibodies leaking from the serum, potentially leading to false-positive re-
sults. Two major methods can be used in combination to determine
local toxoplasma antibody production versus systemic toxoplasma,
namely, speciﬁc IgG. The ﬁrst is the Goldmann–Witmer coefﬁcient
(GWC) (Desmonts, 1966). This coefﬁcient is calculated based on the de-
termination of the speciﬁc versus total IgG levels in the serumand aque-
ous humor. Its sensitivity is around 50% (Garweg et al., 2000; Robert-
Gangneux et al., 2004; Talabani et al., 2009). The second is a similar
method using ELISA to compare the levels of toxoplasma-speciﬁc anti-
bodies versus mumps virus–speciﬁc antibodies, instead of measuring
total IgG (Turunen et al., 1983; Villard et al., 2003).
Yet in some cases, if the blood-retinal barrier is ruptured, the GWC
(Desmonts et al., 1960) is unable to distinguish between systemic and
local toxoplasma-speciﬁc antibodies in the aqueous humor. This is why
using WB to determine a toxoplasma-speciﬁc antibody recognition pro-
ﬁle is of great value in this context. As well as having been developed
for the diagnosis of congenital toxoplasmosis, a WB analysis of serum
and paired aqueous humor sampled the same day is able to determine
the recognition proﬁle. Any observed difference, namely, 1 ormore differ-
ent bands, signiﬁes the presence of toxoplasma-speciﬁc ocular antibodies,
revealing an OT (Talabani et al., 2009; Villard et al., 2003). While the sen-
sitivity of WB is similar to that of GWC, the former achieves higher spec-
iﬁcity (N95%) and is less inﬂuenced by rupture of the blood-retinal barrier
(Robert-Gangneux and Darde, 2012). The combination of GWC, PCR, and
WB has been shown to improve the sensitivity of biological diagnosis,
which can reach up to 83% (Fekkar et al., 2011; Villard et al., 2003). If
both the serology and PCR are negative, other causative infectious and
noninfectious diseases should be investigated (Kijlstra et al., 1989).
5.3. Follow-up of immunosuppressed patients (Fig. 10)
The incidence of opportunist toxoplasmosis is probably underestimated
and depends highly on the prevalence of infection, well known in Europe
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Fig. 8. Comparison of immunoblot IgG and IgMwith pairedmother (M) and infant (i) at birth.
1. Absence of IgM and same proﬁle of IgG in favor of passive transmission of maternal IgG.
2. Same proﬁle for IgG and different proﬁle IgM (arrows) conﬁrming congenital toxoplasmosis.
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sis is an opportunistic infection that carries the risk of complications in AIDS
patients and those having received hematopoietic stem cell transplant
(HSCT) and solid organ transplant (SOT). In the case of immunodeﬁciency,
2 different populations are at risk: toxoplasma-naive patients are at risk for
acute severe and lethal toxoplasmosis, inwhich the diagnosis of infection is
an emergency (Aubert et al., 1996; Chandrasekar and Momin, 1997; Luft
and Remington, 1992; Petersen et al., 2006), and patients with latent toxo-
plasmosis who are at risk for reactivation and secondary disseminated in-
fection. Diagnosis in these patients is often challenging, ﬁrstly owing to
thenonspeciﬁc clinical features of toxoplasmosis. Serology is essential to es-
timate if the patients are at risk for reactivation or not and could be valuable
in emergency diagnosis (Bretagne et al., 2000; Costa et al., 2000).Moreover,
serological data should take into account the toxoplasma status of both
donors and recipients (Fig. 8). Nevertheless, in this population, serology
is often of limited interest due to immune deﬁciency impacting the B-
cell count and interfering treatments, such therapeutic immunoglobu-
lin containing anti-toxoplasma antibodies. Immunological deﬁciency
may lead to multiorgan failure in some cases or a rapid spread of the
pathogen. Parasite detection by PCR is therefore strongly recommended
when serology is negative, with PCR offering high sensitivity in these
settings (Martino et al., 2005).
5.3.1. AIDS-positive patients (Fig. 10A)
In AIDS-positive patients, the cellular immunity is weakened and
profoundly impaired in the late stages of infection. When the CD4+ T
count is b100 cells/μL, there can be a risk of disease reactivation or se-
vere acute toxoplasmosis. Toxoplasmic encephalitis following a reacti-
vation of latent cysts is the most predominant disease (Luft and
Remington, 1992; Weiss and Dubey, 2009). Active retroviral therapy
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toxoplasmosis to fall dramatically. Other organs can be secondarily in-
fected by disseminated infection, including the lungs, eyes, liver, and
bone marrow (Rabaud et al., 1996). Latent chronic infection is diag-
nosed by positive in peripheral blood, and prevention methods using
cotrimoxazole are recommended for patients with higher risk of toxo-
plasmosis. When serology is negative, there is a risk of acute toxoplas-
mosis, and hygienic and dietetic preventive measures are advised,
with serological follow-up according to the CD4+ cell count.
5.3.2. Transplant patients (Fig. 10B and C)
Serological screening of donors and recipients prior to transplanta-
tion enables the mismatch and identiﬁcation of patients at higher risk
for toxoplasmosis to be clearly deﬁned.
In SOT recipients (Fig. 10B), the highest risk of reactivation of toxo-
plasma in the donor graft and disseminated secondary infection occurs
in cases involving chronically infected seropositive donors (D+) and
toxoplasma-seronegative recipients (R−), especially in cases of heart
or heart-lung transplant. The immunosuppressive status leads to the
rupture of cysts contained in transplant and a disseminated active infec-
tion (Fernandez-Sabe et al., 2012; Morris et al., 2010; Rogers et al.,
2008). Clinical symptoms usually occur within the ﬁrst 3 months aftertransplantation. The incidence of toxoplasmosis in seronegative heart
recipients receiving an organ from a seropositive donor (mismatch
D+/R−) has been reported as high as 50–75% in the absence of pro-
phylaxis (Gallino et al., 1996), and prevention with cotrimoxazole
is recommended for patients at a higher risk for toxoplasmosis
(Cavattoni et al., 2010; Derouin and Pelloux, 2008). Cases of trans-
mission in noncardiac SOT recipients are less frequent. Transmis-
sion from a seropositive donor to a seropositive recipient (D+/
R+) is possible, though it is difﬁcult to differentiate between a
transplant-resulting transmission and a reactivation of latent in-
fection in the recipient (Robert-Gangneux et al., 2000). In R−/D−
transplantation, there is no risk of parasite transmission. Seronegative
recipients are susceptible to acute toxoplasmosis infection via con-
sumption of contaminated food and hygienic and dietetic measure
must be implemented in these cases.
Toxoplasmosis following allogeneic HSCT remains a cause of severe
infection associatedwith a highmortality rate. The highest risk of trans-
mission resulting from reactivation is observed in seropositive recipi-
ents following allogeneic HSCT (Bories et al., 2012; Derouin and
Pelloux, 2008). The onset of clinical symptoms generally occurs within
the ﬁrst 2 months after transplantation. In autologous HSCT, transmis-
sion is rare (Geissmann et al., 1994).
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row transplantation is estimated at 0.6–6% in seropositive allogeneic
transplant recipients, resulting in a mortality rate of 60–90% (Small
et al., 2000). Serological screening of donors and recipients prior to
transplantation (Fig. 10C) enables the identiﬁcation of patients at higher
risk for toxoplasmosis, essentially consisting of seropositive recipients,
and a reactivation of latent infection (R+/D− or R+/D+). A prevention
strategy with cotrimoxazole can then be initiated for these patients.
There is no risk of transmission inHSCT cases in R− recipientswith a se-
ropositive and chronically infected donor (R+), nor is there any risk of
transmission in seronegative recipients (R−) receiving transplant from
a seronegative donor, although these patients are susceptible to acute
toxoplasmosis infection through consumption of contaminated food
and hygienic and dietetic measures must therefore be implemented
(Fig. 8C). The transmission of T. gondii to a seronegative recipient from
a seropositive donor (R−/D+) is possible if the donor had a recent
and active acquired infection, with tachyzoites present in the blood.
There is no risk of transmission in cases of HSCT in mismatch R−/D+
(chronically infected). Serological follow-up combined with PCR after
allogeneic HSCT is recommended in all patients at risk for toxoplasmosis
(Fricker-Hidalgo et al., 2009).
6. Conclusions
Despite initial screening providing the medical beneﬁts of early
treatment and appropriate medical care, it is a costly method, and the
availability of these tests according the clinical and epidemiological
grounds must be established. Serological diagnosis becomes a highly
complex issue as soon as we look at less developed locations that
lack the technology. We should highlight the fact that all medical
laboratories should refer theirmore complex cases to a reference center,
assuming that this center has the reference methods necessary to solve
these complex cases. In France, a National Reference Center was createdin 2006 based on a network of reference laboratories. This means that
experts can share their methods and skills, providing help and support
to all French medical laboratories and health professionals.
Finally, universal monthly maternal screening for congenital toxo-
plasmosis, with follow-up and treatment designed according to French
protocols, has been found to be cost-saving if the methods are well
adapted to the local seroprevalence (Stillwaggon et al., 2011; Wallon
et al., 2013).
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